Cel-Sci Corporation (CVM)
Stock Price:
$12.71 USD
-0.34 (-2.61%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
490.91M |
| Revenue (ttm) |
606,739 |
| Net Income (ttm) |
-29.58M |
| Shares Out |
38.62M |
| EPS (ttm) |
-0.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$12.71 |
| Previous Close |
$13.05 |
| Change ($) |
-0.34 |
| Change (%) |
-2.61% |
| Day's Open |
13.05 |
| Day's Range |
12.42 - 13.06 |
| Day's Volume |
287,057 |
| 52-Week Range |
6.00 - 18.00 |
More Stats
| Market Cap |
490.91M |
| Enterprise Value |
483.26M |
| Earnings Date (est) |
Dec 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.62M |
| Float |
36.90M |
| EPS (basic) |
-0.81 |
| EPS (diluted) |
-0.83 |
| FCF / Share |
-0.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.78M |
| Short Ratio |
16.48 |
| Short % of Float |
26.54% |
| Beta |
2.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
809.10 |
| PB Ratio |
26.51 |
| Revenue |
606,739 |
| Operating Income |
-25.96M |
| Net Income |
-29.58M |
| Free Cash Flow |
-17.11M |
| Net Cash |
7.65M |
| Net Cash / Share |
0.20 |
| Gross Margin |
-2,010.18% |
| Operating Margin |
-4,278.33% |
| Profit Margin |
-4,454.90% |
| FCF Margin |
-2,820.63% |
| ROA |
-46.11% |
| ROE |
-293.41% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.00*
(65.22% upside)
Low
19.0
Current: $12.71
High
23.0
Target: 21.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.54 | 0.55 | 0.07 | 0.29 | 0.66 | 0.26 | 0.16 | 0.25 | 0.96 | 0.15 |
| Revenue Growth | -2.13% | 693.18% | -75.79% | -56.64% | 148.98% | 65.45% | -37.32% | -73.37% | 523.71% | - |
| Gross Profit | 0.54 | 0.55 | 0.07 | 0.29 | 0.66 | 0.26 | 0.16 | 0.25 | 0.96 | 0.15 |
| Operating Income | -20.12 | -16.70 | -21.34 | -23.65 | -32.39 | -25.67 | -19.87 | -17.24 | -17.99 | -18.56 |
| Net Income | -22.13 | -31.85 | -14.43 | -11.51 | -34.69 | -27.35 | -9.23 | -15.48 | -25.71 | 10.48 |
| Shares Outstanding | 31.17 | 17.00 | 7.89 | 4.87 | 3.30 | 2.35 | 1.21 | 1.01 | 0.83 | 0.81 |
| Earnings Per Share | -0.71 | -1.87 | -1.91 | -2.37 | -10.51 | -12.21 | -16.50 | -19.50 | -37.25 | -15.00 |
| Operating Cash Flow | -16.32 | -13.39 | -13.79 | -23.08 | -23.83 | -22.93 | -13.55 | -12.19 | -22.56 | -12.80 |
| Capital Expenditures | -0.18 | - | -0.01 | -0.03 | -0.07 | -0.10 | -0.10 | -0.05 | -0.22 | -0.53 |
| Free Cash Flow | -16.50 | -13.39 | -13.80 | -23.11 | -23.91 | -23.03 | -13.65 | -12.24 | -22.77 | -13.33 |
| Cash & Equivalents | 10.12 | 11.98 | 4.04 | 4.74 | 7.70 | 10.63 | 2.11 | 5.61 | 5.93 | 26.59 |
| Total Debt | 13.51 | 13.38 | 14.21 | 13.01 | 27.57 | 1.12 | 1.13 | 8.09 | 6.10 | 1.10 |
| Net Cash / Debt | -3.39 | -1.40 | -10.17 | -8.27 | -19.88 | 9.51 | 0.98 | -2.48 | -0.17 | 25.49 |
| Assets | 27.62 | 29.59 | 22.92 | 24.89 | 28.55 | 19.23 | 10.84 | 16.07 | 18.63 | 37.80 |
| Liabilities | 22.49 | 29.59 | 26.26 | 25.57 | 33.32 | 8.79 | 4.14 | 9.04 | 9.55 | 9.95 |
| Book Value | 5.13 | - | -3.34 | -0.68 | -4.76 | 10.44 | 6.70 | 7.03 | 9.08 | 27.85 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cel-Sci Corporation |
| Country |
United States |
| CEO |
Geert R. Kersten |
Stock Information
| Ticker Symbol |
CVM |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: CVM |
| IPO Date |
January 1, 1987 |
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.